Clinical trials: Genomic
Keloid
Keloid Tissue Bank
Much progress in treatment of various tumors has been made in the laboratory and the results have been brought back to the patients, i.e. from bench to bedside.
- Trial name
- NCT01425437
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- Tirgan, Michael H., M.D.
Non Small Cell Lung Cancer, Microbiome
BioForte Technology for in Silico Identification of Candidates for a New Microbiome-based Therapeutics and Diagnostics
The goal of the project is to develop and validate the BioForte technology. Its main functionality should be to in silico determine candidates for novel microbiome-based therapeutics and diagnostics.
- Conditions
- Non Small Cell Lung Cancer, Microbiome, Metagenome, Immunotherapy
- Trial name
- NCT04136470
- Testing
- Collection of stool, blood (PBMC) and biopsy (FFPE)
- Where
- 10 sites in Poland
- Volunteers
- 130 people
- Sponsor
- Ardigen
Pregnancy
Idealizing Pregnancy Outcome With Single Blastocyst Transfer in a FET Cycle
Single embryo transfer (SET) has been advocated as a means of reducing the risk of multiple pregnancies, but has meant a reduction in pregnancy risk per embryo transfer.
- Trial name
- NCT01987856
- Testing
- Blastocyst morphology
- Where
- Turkey (Türkiye)
- Volunteers
- healthy volunteers welcome
- Sponsor
- Antalya IVF
Bladder Cancer, Genomic Instability
Bladder Cancer and Neoadjuvant Chemotherapy Efficiency Before Cystectomy
This study will allow the investigators to better assess the efficiency of neoadjuvant chemotherapy before cystectomy by training a predictive model on different patient cohorts with bladder cancer.
- Trial name
- SELECT (NCT06294054)
- Testing
- neoadjuvant chemotherapy with cisplatine
- Where
- 7 sites in France
- Volunteers
- 707 people
- Sponsor
- University Hospital, Rouen
NAFLD, Precision Medicine
The Liver BIoBank Lombardia of Fatty Liver
NAFLD is most frequently linked to excess adiposity, insulin resistance and cardiometabolic risk factors, it has become the leading cause of liver disease worldwide, and is associated with increased mortality due to multiple…
- Conditions
- NAFLD, Precision Medicine, Cardiovascular Diseases
- Trial name
- NCT06566105
- Testing
- precision medicine approach
- Where
- Italy
- Volunteers
- 2,500 people, healthy volunteers welcome
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Non-Small Cell Lung Cancer
Personalized Adaptive Radiation Therapy With Individualized Systemic Targeted Therapy (PARTIST) for Locally Advanced, Non-small Cell Lung Cancer With Genomic Driver Mutations
Hypotheses: Short-term - Targeted therapy with erlotinib or crizotinib plus PART (Personalized Adaptive Radiation Therapy) will be safe and will yield favorable outcomes in patients with stage III, EGFR (Epidermal Growth Factor…
- Trial name
- NCT02277457
- Testing
- PET-Adaptive RT, Erlotinib, Crizotinib
- Where
- United States
- Sponsor
- University of Michigan Rogel Cancer Center
Trisomy 21, Trisomy 18
Study of the Efficacy of New Non-invasive Prenatal Tests for Screening for Fetal Trisomies Using Maternal Blood
Each year, 450,000 Canadian women become pregnant and, as a result of their participation in prenatal screening for Down syndrome, approximately 10,000 of them will have an amniocentesis (i.e.
- Conditions
- Trisomy 21, Trisomy 18, Trisomy 13
- Trial name
- PEGASUS (NCT01925742)
- Testing
- Integrated prenatal screening for Down's syndrome, Serum QUAD Assay for aneuploidy screening, Semiconductor MPSS NIPT assay using ccfDNA in maternal blood
- Where
- 5 sites in Canada
- Volunteers
- 3,819 people, healthy volunteers welcome
- Sponsor
- CHU de Quebec-Universite Laval
Thoracic Organ Transplantation
Genome Transplant Dynamics
Study Description: Heart and lung transplants can save lives, but long-term success is often limited by organ rejection that is hard to detect early.
- Trial name
- NCT02423070
- Where
- 7 sites in United States
- Volunteers
- 991 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Idiopathic Pulmonary Fibrosis
Genomic and Proteomic Analysis of Disease Progression in Idiopathic Pulmonary Fibrosis (IPF)
The purpose of the study is to identify genetic and biologic markers that may predict the loss of lung function due to idiopathic pulmonary fibrosis.
- Trial name
- GAP (NCT00373841)
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- University of Pittsburgh
Efficacy
Genome-Based Assessment of Niraparib (ZEJULA®) Efficacy in Advanced Solid TumorS With Homologous Recombination Deficiency
Investigational Products: Niraparib Period: 3 years after IRB/EC approval Indication: Adult patients with histologically confirmed and locally advanced, unresectable, or metastatic solid tumors having known or suspected…
- Trial name
- NCT06237205
- Testing
- Niraparib
- Volunteers
- 33 people
- Sponsor
- Korea University Anam Hospital
Prostate Cancer, Bladder Cancer
Decipher Genomics Resource for Intelligent Discovery
To prospectively evaluate the utility of genomic expression data and whole slide digital pathology image data as a tool to better characterize the tumors of individual patients, and to understand how genomic and histologic…
- Conditions
- Prostate Cancer, Bladder Cancer, Renal Cancer
- Trial name
- GRID® (NCT02609269)
- Testing
- Decipher Cancer Classifier
- Volunteers
- 1,000,000 people
- Sponsor
- GenomeDx Biosciences Corp
Idiopathic Interstitial Pneumonias
Peripheral Blood Biomarkers in Idiopathic Interstitial Pneumonias
We hypothesize that a peripheral blood biomarker or biological signature (gene or protein expression pattern) of idiopathic interstitial pneumonias (IIPs) will simplify and improve the accuracy of diagnosis of IIP and diagnose…
- Trial name
- NCT01151527
- Where
- 2 sites in United States
- Volunteers
- 269 people, healthy volunteers welcome
- Sponsor
- Duke University
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Study of Pembrolizumab in Subjects With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-Line Therapy With Platinum and Fluoropyrimidine: Integration of Molecular Subtypes Through Integrative Genomic Analysis
This is a single-arm, single-center, open-label trial of pembrolizumab (MK-3475) in subjects with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma who have progressed after failure of any combination…
- Trial name
- NCT02589496
- Testing
- pembrolizumab
- Where
- South Korea
- Volunteers
- 80 people
- Sponsor
- Samsung Medical Center
Chronic Kidney Disease, Hypertension
Genetic Testing to Understand and Address Renal Disease Disparities Across the United States
GUARDD-US is a prospective, multicenter, unblinded, two arm randomized pragmatic clinical trial. Participants will be randomized in a 1:1 ratio to immediate APOL1 gene testing and return of results (ROR) to participant and…
- Trial name
- GUARDD-US (NCT04191824)
- Testing
- Timing of return of results
- Where
- 14 sites in United States
- Volunteers
- 6,789 people
- Sponsor
- Duke University
Non-small Cell Lung Cancer
Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)
The goal of this clinical study is to learn more about the study drug, sacituzumab govitecan-hziy (SG), and its dosing in combination with pembrolizumab or pembrolizumab and a platinum agent (carboplatin or cisplatin), in…
- Trial name
- EVOKE-02 (NCT05186974)
- Testing
- Sacituzumab Govitecan-hziy (SG), Pembrolizumab, Carboplatin
- Where
- 101 sites in United States, Australia and 10 more
- Volunteers
- 193 people
- Sponsor
- Gilead Sciences
Ring 14
Multi-Dimensional Genomic Dissection of Ring Chromosome 14 Syndrome
MD-RING will explore the hypothesis that position effects and TAD alterations act as an unprecedented pathomechanism in r(14)S. This will contribute to a better understanding of genotype-to-phenotype correlations, creating an…
- Trial name
- NCT06813469
- Testing
- LRS analysis
- Where
- Italy
- Volunteers
- 15 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Cancer-associated Thrombosis, Genetic Predisposition
A New Clinic-Genetic Risk Score for Predicting Venous Thromboembolic Events in Cancer Patient
Venous thromboembolism (VTE) is a common disease in cancer patients and one of the major causes of cancer-associated mortality. Risk for developing VTE increases when cancer patients are receiving chemotherapy.
- Trial name
- ONCOTHROMB (NCT03114618)
- Where
- 9 sites in Spain
- Volunteers
- 416 people
- Sponsor
- Andres muñoz
Ventricular Tachycardia, Atrial Fibrillation
Defining the Risk of Ventricular Tachycardia in Genetic Forms of Early-onset Atrial Fibrillation
To use programmed ventricular stimulation at the time of AF ablation to define the prevalence and mechanism of inducible ventricular tachycardia (VT); pace-mapping to define the site of origin of ventricular arrhythmias; and…
- Trial name
- NCT06647459
- Testing
- EP Study
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University Medical Center
Respiratory Distress Syndrome, Adult
Understanding the Role of Genes and Biomarkers in the Inflammation and Blood Clotting Process in Children With Acute Lung Injury
Acute lung injury (ALI)/Acute Respiratory Distress Syndrome (ARDS) is a severe lung condition that causes respiratory failure. This study will examine if differences in genes and biomarkers involved in the inflammation and blood…
- Trial name
- PALI (NCT00605527)
- Where
- 5 sites in United States
- Volunteers
- 396 people
- Sponsor
- University of California, San Francisco
Diarrhea, Infantile, Enteropathy
Whole Genome Sequencing Versus Whole Exome Sequencing for Congenital Diarrhea and Enteropahty
This study will seek to determine if whole genome sequencing (WGS) improves diagnostic rates, and outcomes for congenital diarrhea and enteropathy (CODE) patients.
- Trial name
- NCT04528303
- Testing
- Whole genome sequencing, Whole exome sequencing
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Children's Hospital of Fudan University